Compare IMA & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMA | EQ |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.4M | 64.5M |
| IPO Year | N/A | 2018 |
| Metric | IMA | EQ |
|---|---|---|
| Price | $6.85 | $1.83 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $16.00 | $1.00 |
| AVG Volume (30 Days) | 45.4K | ★ 483.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 13.89 |
| 52 Week Low | $5.70 | $0.29 |
| 52 Week High | $17.50 | $2.35 |
| Indicator | IMA | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 49.83 | 63.79 |
| Support Level | $6.65 | $1.33 |
| Resistance Level | $7.17 | $2.30 |
| Average True Range (ATR) | 0.39 | 0.15 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 32.25 | 72.92 |
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.